Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

Symptom Management and Supportive Care

At a Glance

Supportive care is the main approach for Huntington disease-like 1 because there is no current cure. A multidisciplinary team can individualize treatment for movement, mood, swallowing, balance, safety, and daily function while monitoring medication risks and caregiver needs.

Because Huntington disease-like 1 (HDL1) has no current cure, the focus of medical care is on managing symptoms and maintaining the best possible quality of life. This approach, known as supportive care, aims to treat the person’s specific symptoms rather than the underlying genetic cause [1][2].

Your Multidisciplinary Care Team

No single doctor can manage all the facets of HDL1. The “gold standard” for care is a multidisciplinary team—a group of specialists who work together to address movement, thinking, and physical safety [3][2].

  • Movement Disorder Specialist: A neurologist with extra training in conditions like Huntington’s and prion diseases who oversees medication.
  • Physical Therapist (PT): Focuses on balance, walking safety, and strength to prevent falls [4].
  • Occupational Therapist (OT): Helps adapt daily activities (like eating or dressing) and recommends home safety equipment.
  • Speech-Language Pathologist (SLP): Critically important for managing speech changes and, most importantly, swallowing safety [5].
  • Psychiatrist or Neuropsychiatrist: Manages mood changes, psychosis, or severe irritability. (A neuropsychologist may also be involved to formally assess cognition and functional decline) [6].
  • Additional Support: The team often includes a dietitian, a social worker, a genetic counselor, nursing support, and a palliative-care clinician.

Managing Movement Symptoms

Treatment for movements is highly individualized. What works for one person may not be right for another, and medications must be carefully balanced against their side effects.

  • Chorea (Involuntary Movements): Medications called VMAT2 inhibitors, such as deutetrabenazine or tetrabenazine, are sometimes used off-label to “quiet” these movements, based primarily on evidence and approvals for Huntington’s chorea rather than specific HDL1 trials [7][8].
    • Caution: These drugs can cause or worsen depression, suicidal thoughts, marked sleepiness, “foggy” thinking, or parkinsonism (stiffness). Your doctor will likely start with a low dose and increase it slowly while monitoring your mood and alertness [9][10].
  • Ataxia (Incoordination): There are fewer medications for balance issues. Instead, care focuses on physical therapy. PTs may use supervised gait training and aerobic exercise to help maintain mobility for as long as possible [4][11].
  • Rigidity or Irritability: If movements are accompanied by severe irritability or psychosis, your doctor may suggest an antipsychotic medication. These can help with both mood and movement.
    • Caution: Antipsychotics carry major risks, including worsening physical stiffness (rigidity), excessive sedation, metabolic effects, heart rhythm (QT) effects, and a worsened risk of swallowing problems and falls. This requires an individualized risk-benefit assessment [12][13].

The Critical Role of Swallowing Care

One of the most significant risks in progressive brain diseases like HDL1 is dysphagia, or difficulty swallowing. If food or liquid “goes down the wrong pipe” into the lungs, it can cause aspiration pneumonia, a serious lung infection [5][14].

Because you can sometimes have “silent aspiration”—where food enters the lungs without causing a cough—it is vital to have regular evaluations by an SLP [5]. They may recommend texture changes (like thickening liquids) or postural changes (like learning to tuck your chin). However, do not independently alter liquid thickness or posture without an SLP’s guidance. Interventions must be selected after an individualized clinical assessment, potentially including a videofluoroscopy or FEES, as the wrong strategy can cause dehydration, leave residue in the throat, or actually worsen aspiration [15].

Seek emergency care immediately if you notice warning signs of aspiration pneumonia or dehydration, such as sudden fever, shortness of breath, chest pain, persistent severe cough, or reduced urine after suspected choking.

Daily Care and Monitoring

Both the patient and the care partner are the most important observers of changes. Watch for and report these “red flags” to your team:

  • Eating and Health Changes: Frequent coughing during meals, a “wet” sounding voice, significant weight loss, dehydration, or constipation [5].
  • Mood Shifts and Emergencies: New or worsening sadness, withdrawal, or sudden outbursts of anger [6]. Call emergency crisis services immediately for suicidal thoughts, self-harm, or severe, dangerous aggression.
  • Fall Risks: Any “near-falls” or changes in how steady a person is when turning or standing up [16].
  • Caregiver Strain: Monitor for caregiver exhaustion, sleep deprivation, and burnout.

By tracking these changes and working closely with a specialized team, you can adjust your care plan in real-time to ensure safety and comfort throughout the course of the disease [1][2].

Common questions in this guide

What does supportive care mean for someone with HDL1?
Supportive care for Huntington disease-like 1 focuses on relieving symptoms and preserving safety, comfort, and quality of life rather than curing the genetic cause. It may include therapy, medication, swallowing support, mood care, nutrition, and help with daily activities. The plan should change as symptoms and priorities change.
Which specialists should be involved in HDL1 care?
A movement-disorder neurologist can coordinate with physical, occupational, and speech-language therapists, psychiatry, a dietitian, social work, genetic counseling, nursing, and palliative care. This team can address movement, balance, swallowing, mood, cognition, nutrition, home safety, and caregiver needs.
Are medications available for HDL1 chorea?
Deutetrabenazine or tetrabenazine, medicines called VMAT2 inhibitors, may be used off-label to reduce chorea, or involuntary movements. They can cause or worsen depression, suicidal thoughts, sleepiness, slowed thinking, or stiffness, so the prescriber usually starts with a low dose and monitors closely.
How can swallowing problems in HDL1 be evaluated and managed?
A speech-language pathologist should assess swallowing because aspiration can occur without coughing. The therapist may recommend changes in food or liquid texture, posture, or further testing such as videofluoroscopy or FEES, a camera-based swallowing exam. Do not make these changes on your own because the wrong strategy can worsen aspiration or dehydration.
What can help with HDL1 balance problems and falls?
Physical therapy can use supervised gait training, strength work, and aerobic exercise to help maintain mobility. An occupational therapist can adapt daily tasks and recommend home safety equipment, while the care team monitors near-falls and changes in steadiness.
When should someone with HDL1 get urgent medical help?
Seek emergency care for sudden fever, shortness of breath, chest pain, a persistent severe cough, or reduced urine after suspected choking, because these can signal aspiration pneumonia or dehydration. Get immediate crisis help for suicidal thoughts, self-harm, or severe dangerous aggression.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Huntington disease-like 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific motor symptom—the 'dance-like' chorea or the 'unsteady' ataxia—should we prioritize for treatment right now?
  2. 2.If we start a medication off-label for chorea, how will we monitor for side effects like depression or increased sleepiness?
  3. 3.Can you refer us to a speech-language pathologist for a baseline swallowing study?
  4. 4.How often should we reassess the care plan as the disease changes?
  5. 5.What are our options for managing mood or personality changes if they become distressing?

References

References (16)
  1. 1

    A novel 8-octapeptide repeat insertion in PRNP causing Huntington disease-like 1 in a Chinese family: a case report and literature review.

    Ni J, Zheng F, Yu L, et al.

    Journal of medical genetics 2025; (62(10)):647-652 doi:10.1136/jmg-2024-110520.

    PMID: 40461170
  2. 2

    Genetic counseling for prion disease: Updates and best practices.

    Goldman JS, Vallabh SM

    Genetics in medicine : official journal of the American College of Medical Genetics 2022; (24(10)):1993-2003 doi:10.1016/j.gim.2022.06.003.

    PMID: 35819418
  3. 3

    Familial Creutzfeldt-Jakob Disease: Case report and role of genetic counseling in post mortem testing.

    Clift K, Guthrie K, Klee EW, et al.

    Prion 2016; (10(6)):502-506 doi:10.1080/19336896.2016.1254858.

    PMID: 27929804
  4. 4

    Clinical recommendations to guide physical therapy practice for Huntington disease.

    Quinn L, Kegelmeyer D, Kloos A, et al.

    Neurology 2020; (94(5)):217-228 doi:10.1212/WNL.0000000000008887.

    PMID: 31907286
  5. 5

    Management of dysphagia in Huntington's disease: a descriptive review.

    Pizzorni N, Pirola F, Ciammola A, Schindler A

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020; (41(6)):1405-1417 doi:10.1007/s10072-020-04265-0.

    PMID: 31989345
  6. 6

    Antidopaminergic medications in Huntington's disease.

    Tan AM, Geva M, Goldberg YP, et al.

    Journal of Huntington's disease 2025; (14(1)):16-29 doi:10.1177/18796397241304312.

    PMID: 39973394
  7. 7

    An MDS Evidence-Based Review on Treatments for Huntington's Disease.

    Ferreira JJ, Rodrigues FB, Duarte GS, et al.

    Movement disorders : official journal of the Movement Disorder Society 2022; (37(1)):25-35 doi:10.1002/mds.28855.

    PMID: 34842303
  8. 8

    Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.

    Furr Stimming E, Claassen DO, Kayson E, et al.

    The Lancet. Neurology 2023; (22(6)):494-504 doi:10.1016/S1474-4422(23)00127-8.

    PMID: 37210099
  9. 9

    Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.

    Claassen DO, Carroll B, De Boer LM, et al.

    Journal of clinical movement disorders 2017; (4()):3 doi:10.1186/s40734-017-0051-5.

    PMID: 28265459
  10. 10

    Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment.

    Molnar MJ, Molnar V, Fedor M, et al.

    Frontiers in psychiatry 2021; (12()):825532 doi:10.3389/fpsyt.2021.825532.

    PMID: 35222108
  11. 11

    Home-Based Exercise to Improve Motor Functions, Cognitive Functions, and Quality of Life in People with Huntington's Disease: A Systematic Review and Meta-Analysis.

    Al-Wardat M, Schirinzi T, Hadoush H, et al.

    International journal of environmental research and public health 2022; (19(22)) doi:10.3390/ijerph192214915.

    PMID: 36429634
  12. 12

    Antipsychotic drugs in Huntington's disease.

    Unti E, Mazzucchi S, Palermo G, et al.

    Expert review of neurotherapeutics 2017; (17(3)):227-237 doi:10.1080/14737175.2016.1226134.

    PMID: 27534434
  13. 13

    Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.

    Coppen EM, Roos RA

    Drugs 2017; (77(1)):29-46 doi:10.1007/s40265-016-0670-4.

    PMID: 27988871
  14. 14

    Clinical predictors and neural correlates for compromised swallowing safety in Huntington disease.

    Schumann-Werner B, Dogan I, Mirzazade S, et al.

    European journal of neurology 2021; (28(9)):2855-2862 doi:10.1111/ene.14953.

    PMID: 34077591
  15. 15

    Dysphagia, Fear of Choking and Preventive Measures in Patients with Huntington's Disease: The Perspectives of Patients and Caregivers in Long-Term Care.

    Kalkers K, Schols JMGA, van Zwet EW, Roos RAC

    The journal of nutrition, health & aging 2022; (26(4)):332-338 doi:10.1007/s12603-022-1743-6.

    PMID: 35450988
  16. 16

    Motor-cognitive dual-task deficits in individuals with early-mid stage Huntington disease.

    Fritz NE, Hamana K, Kelson M, et al.

    Gait & posture 2016; (49()):283-289 doi:10.1016/j.gaitpost.2016.07.014.

    PMID: 27474949

This page is for informational purposes only and does not constitute medical advice. A neurologist and the rest of the care team should guide medication, swallowing, safety, and caregiver decisions for a specific person.